Answers are grounded in this paper and cite their sources.
Clinical guideline recommends against PSA-based prostate cancer screening in the general male population, highlighting harms outweigh benefits.
DESCRIPTION: Update of the 2008 U.S. Preventive Services Task Force (USPSTF) recommendation statement on screening for prostate cancer. METHODS: The USPSTF reviewed new evidence on the benefits and harms of prostate-specific antigen (PSA)-based screening for prostate cancer, as well as the benefits and harms of treatment of localized prostate cancer. RECOMMENDATION: The USPSTF recommends against PSA-based screening for prostate cancer (grade D recommendation).This recommendation applies to men in the general U.S. population, regardless of age. This recommendation does not include the use of the PSA test for surveillance after diagnosis or treatment of prostate cancer; the use of the PSA test for this indication is outside the scope of the USPSTF.
No takes yet. Share an insight, caveat, or question.
Virginia A. Moyer (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: